Galapagos Genomics NV, a Belgian functional genomics company, hasannounced a research collaboration with Bayer Yakuhin in Japan to identify the function of proteins encoded by newly-discovered genes involved in asthma.
Under the terms of the agreement, Bayer will provide Galapagos with a proprietary collection of human genes associated with asthma from which the latter will construct recombinant adenoviruses, using its PhenoSelect expression platform. Financial terms of the collaboration were not disclosed.
Onno van de Stolpe, Galapagos' chief executive, said the deal is the firm's first collaboration "with a top-tier pharmaceutical company and it is therefore an important milestone." He added that the deal "is an endorsement of our platform as an important tool in the rapid identification and validation of drug targets out of large gene collections."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze